Compounds > baclofen
Page last updated: 2024-10-23

baclofen and Pyrosis

baclofen has been researched along with Pyrosis in 10 studies

Research Excerpts

ExcerptRelevanceReference
"The intensity of heartburn symptom in response to esophageal acid infusion was significantly greater with baclofen than the placebo (P = 0."9.30Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation. ( Chen, CL; Hung, JS; Lei, WY; Liu, TT; Wong, MW; Yi, CH, 2019)
"Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)."9.17Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013)
"Baclofen was associated with a significant decrease in percent upright reflux by 24-h pH monitoring and a significant improvement in belching, regurgitation and overall symptom score."9.16Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012)
"Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p."9.10Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003)
"Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially."6.82Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016)
"Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h."6.75Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010)
"Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring."5.30Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019)
"The intensity of heartburn symptom in response to esophageal acid infusion was significantly greater with baclofen than the placebo (P = 0."5.30Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation. ( Chen, CL; Hung, JS; Lei, WY; Liu, TT; Wong, MW; Yi, CH, 2019)
"Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)."5.17Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013)
"Baclofen was associated with a significant decrease in percent upright reflux by 24-h pH monitoring and a significant improvement in belching, regurgitation and overall symptom score."5.16Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012)
"It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing."5.15Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. ( Bian, A; Huff, FJ; Jones, DS; Stamler, D; Vakil, NB, 2011)
"Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p."5.10Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003)
"Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially."2.82Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016)
"Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h."2.75Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010)
" Twice-daily dosing of PPI for inadequate gastric acid suppression and the administration of H2-receptor antagonist before bedtime for nocturnal acid reflux, is effective in most cases."2.44[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor]. ( Iwakiri, K; Kawami, N; Kotoyori, M; Sakamoto, C; Sano, H; Tanaka, Y, 2007)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spechler, SJ1
Hunter, JG1
Jones, KM1
Lee, R1
Smith, BR1
Mashimo, H1
Sanchez, VM1
Dunbar, KB1
Pham, TH1
Murthy, UK1
Kim, T1
Jackson, CS1
Wallen, JM1
von Rosenvinge, EC1
Pearl, JP1
Laine, L1
Kim, AW1
Kaz, AM1
Tatum, RP1
Gellad, ZF1
Lagoo-Deenadayalan, S1
Rubenstein, JH1
Ghaferi, AA1
Lo, WK1
Fernando, RS1
Chan, BS1
Paski, SC1
Provenzale, D1
Castell, DO2
Lieberman, D1
Souza, RF1
Chey, WD1
Warren, SR1
Davis-Karim, A1
Melton, SD1
Genta, RM1
Serpi, T1
Biswas, K1
Huang, GD1
Wong, MW1
Hung, JS1
Liu, TT1
Yi, CH1
Lei, WY1
Chen, CL1
Vakil, NB2
Huff, FJ3
Cundy, KC1
Scarpellini, E1
Boecxstaens, V1
Broers, C1
Vos, R1
Pauwels, A1
Tack, J1
Gerson, LB1
Hila, A1
Hirota, WK1
Reilley, S1
Agrawal, A1
Lal, R1
Luo, W1
Castell, D1
Bian, A1
Jones, DS1
Stamler, D1
Cossentino, MJ1
Mann, K1
Armbruster, SP1
Lake, JM1
Maydonovitch, C1
Wong, RK1
Vela, MF1
Tutuian, R1
Katz, PO1
Iwakiri, K1
Kawami, N1
Tanaka, Y1
Sano, H1
Kotoyori, M1
Sakamoto, C1
Fass, R1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550]Phase 3366 participants (Actual)Interventional2012-08-13Completed
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170]208,266 participants (Actual)Interventional2019-09-16Completed
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)[NCT00978016]Phase 2460 participants (Actual)Interventional2009-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Enrolled Participants With Achalasia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

Number of Enrolled Participants With Anxiety and/or Depression

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled125

Number of Enrolled Participants With Aperistalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

Number of Enrolled Participants With Belching Disorders

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled130

Number of Enrolled Participants With Candida Esophagitis.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

Number of Enrolled Participants With Chronic Idiopathic Nausea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled51

Number of Enrolled Participants With Cyclic Vomiting Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled86

Number of Enrolled Participants With Distal Esophageal Spasm

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

Number of Enrolled Participants With Eosinophilic Esophagitis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled16

Number of Enrolled Participants With Esophageal Ulceration.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

Number of Enrolled Participants With Functional Bloating

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled13

Number of Enrolled Participants With Functional Diarrhea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

Number of Enrolled Participants With Functional Dysphagia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled7

Number of Enrolled Participants With Functional Gallbladder Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

Number of Enrolled Participants With Functional Heartburn

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled221

Number of Enrolled Participants With Functional Vomiting

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled32

Number of Enrolled Participants With Gastric Outlet Obstruction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

Number of Enrolled Participants With Globus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

Number of Enrolled Participants With Hypertensive Peristalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

Number of Enrolled Participants With Ineffective Esophageal Motility

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

Number of Enrolled Participants With Irritable Bowel Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled152

Number of Enrolled Participants With Jackhammer Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

Number of Enrolled Participants With Nutcracker Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

Number of Enrolled Participants With Rapid Contraction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

Number of Enrolled Participants With Reflux Esophagus.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled56

Number of Enrolled Participants With Weak Peristalsis I

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled10

Number of Enrolled Participants With Weak Peristalsis II

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled9

Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months

"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group7
Surgical Treatment Group18
Placebo Medical Treatment Group3

Number of Successful Participants With Anxiety and/or Depression.

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

Number of Successful Participants With Belching Disorders

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group12
Placebo Medical Treatment Group2

Number of Successful Participants With Chronic Idiopathic Nausea

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group3
Placebo Medical Treatment Group0

Number of Successful Participants With Cyclic Vomiting Syndrome

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group7
Placebo Medical Treatment Group1

Number of Successful Participants With Functional Bloating

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group0

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

Number of Successful Participants With Functional Diarrhea

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

Number of Successful Participants With Functional Dysphagia

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

Number of Successful Participants With Functional Gallbladder Disorder

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

Number of Successful Participants With Functional Heartburn

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group7
Surgical Treatment Group14
Placebo Medical Treatment Group3

Number of Successful Participants With Functional Vomiting

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group1

Number of Successful Participants With Globus

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

Number of Successful Participants With Irritable Bowel Syndrome

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group10
Placebo Medical Treatment Group3

Number of Successful Participants With Unspecified Functional Bowel Disorder

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group15

Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

Reviews

1 review available for baclofen and Pyrosis

ArticleYear
[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:5

    Topics: Aryl Hydrocarbon Hydroxylases; Baclofen; Cytochrome P-450 CYP2C19; Diet; Drug Administration Schedul

2007

Trials

8 trials available for baclofen and Pyrosis

ArticleYear
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga

2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga

2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga

2019
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga

2019
Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:2

    Topics: Adult; Baclofen; Double-Blind Method; Esophageal Motility Disorders; Esophagus; Female; GABA-B Recep

2019
Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2

    Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esoph

2013
Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016, Volume: 29, Issue:8

    Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Esophageal Sphincter, Lower; Eso

2016
Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease.
    The American journal of gastroenterology, 2010, Volume: 105, Issue:6

    Topics: Adult; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Esophage

2010
Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:8

    Topics: Adult; Aged; Baclofen; Dizziness; Double-Blind Method; Drug Administration Schedule; Fatigue; Female

2011
Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:9

    Topics: Adult; Baclofen; Chest Pain; Double-Blind Method; Eructation; Esophageal pH Monitoring; Female; GABA

2012
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Baclofen; Electric Impedance; Female; GABA Agonists; Gastric Acid; Gastric

2003

Other Studies

1 other study available for baclofen and Pyrosis

ArticleYear
Persistent heartburn in a patient on proton-pump inhibitor.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:4

    Topics: Acupuncture Therapy; Adult; Analgesics; Anti-Ulcer Agents; Baclofen; Bile Reflux; Bilirubin; Electri

2008